Who is sponsoring NCT04582604?

NCT04582604 is sponsored by Chinese PLA General Hospital.

What condition does NCT04582604 study?

NCT04582604 studies Peripheral Blood Stem Cell Transplantation.

Is NCT04582604 still recruiting?

NCT04582604 is currently status unknown. Last updated 20 October 2020.

Last reviewed 2020-10-20 · How we verify

NCT04582604

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ruxolitinib and Decitabine for High Risk Hematological Malignancies

Status unknown Phase 1, PHASE2 Last updated 20 October 2020

What this trial tests

Phase 1, PHASE2 trial testing modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine in Peripheral Blood Stem Cell Transplantation in 60 participants. Status unknown.

Timeline

1 September 2020

Primary endpoint
1 September 2023

30 September 2025

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 September 2020
Primary completion	1 September 2023
Estimated completion	30 September 2025
Sites	1 location across China

Drugs / interventions tested

modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine — full drug profile →

Conditions studied

Peripheral Blood Stem Cell Transplantation — all drugs for Peripheral Blood Stem Cell Transplantation →

Sponsor

Chinese PLA General Hospital

Who can join

Adults 12 to 65, any sex, with Peripheral Blood Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Decitabine intensified Conditioning Regimen in Patients with High Risk hematological malignancies undergoing allogeneic peripheral blood stem cell transplantation.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens.
Hu Q, Bian Q, Rong D, Wang L, et al · · 2023 · cited 190× · PMID 36911202 · DOI 10.3389/fbioe.2023.1110765
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y, Alexander M, Gadina M, O'Shea JJ, et al · · 2021 · cited 92× · PMID 34625141 · DOI 10.1016/j.jaci.2021.08.004
The Impact of Epigenetic Modifications in Myeloid Malignancies.
Venney D, Mohd-Sarip A, Mills KI. · · 2021 · cited 19× · PMID 34065087 · DOI 10.3390/ijms22095013
Role of epigenetics in paediatric cancer pathogenesis & drug resistance.
Leung JY, Chiu HY, Taneja R. · · 2025 · cited 1× · PMID 40055485 · DOI 10.1038/s41416-025-02961-2
Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study.
Wei Y, Qian K, Le N, Wang L, et al · · 2024 · cited 1× · PMID 39243311 · DOI 10.1007/s00277-024-05972-w
Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.
Wei Y, Luan S, Wang L, Wang L, et al · · 2025 · PMID 40901473 · DOI 10.3389/fimmu.2025.1586512

Verify or expand the search:

Other recruiting trials for Peripheral Blood Stem Cell Transplantation

Currently open trials in the same condition.

NCT05961410 — Eltrombopag for Peripheral Blood Stem Cell Harvest · Phase 2 · recruiting
NCT05436418 — The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofet · Phase 1, PHASE2 · recruiting

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04582604 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
Last refreshed: 20 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04582604.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing